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Introduction
Organ fibrosis constitutes a significantly prevalent pathological 
entity associated with high morbidity and mortality and pres-
ents a major biomedical challenge. Although fibrosis may affect 
any tissue of the human body, its presence in the kidney gener-
ally indicates unrelenting progression to chronic renal failure, a 
condition associated with reduced expectancy and quality of life. 
Hence, fibrosis is a convergent pathway for prevalent pathologies 
underlying chronic kidney disease (CKD), such as diabetes, hyper-
tension, and nephrosclerosis (1). Beyond proper blood pressure 
and glycemic controls, therapeutic options to revert or deter the 
progression of fibrosis are very limited. In the last few years, the 
understanding of major metabolic disturbances coexisting with 
kidney fibrosis have shed new light on the pathogenesis of fibro-
sis progression (2). Among these, a drastic reduction in fatty acid 
oxidation (FAO) appears to be critical for the global energy failure 
occurring in the tubulo-interstitial compartment, contributing to 
immune cell infiltration and kidney fibrosis (3, 4). Here, we tested 
whether specific metabolic gain of function in FAO (FAO-GOF) in 
renal tubules was necessary and sufficient to counteract cellular 
and molecular changes associated with kidney fibrosis. Carnitine 
palmitoyl transferase 1A (CPT1A) is a rate-limiting and targetable 
enzyme in this pathway. We found that conditional overexpres-
sion of CPT1A resulted in significant mitigation of fibrosis and 
improvement of renal function in 3 experimental models. This 
was related to enhanced mitochondrial mass, repaired architec-
ture, and bioenergetic recovery. The overexpression of CPT1A was 
also associated with a reduced inflammatory pattern and abroga-
tion of TGF-β–induced epithelial cell damage. In the folic acid 
nephropathy (FAN) model, pathological changes were markedly 
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tin (FN) and smooth muscle actin (aSMA) was also significantly 
reduced in the CPT1A-KI mice (Figure 2, D and E). To confirm 
the beneficial effect of FAO-GOF in kidney fibrosis, the latter was 
assessed by performing unilateral ureteral obstruction (UUO) for 
3 and 7 days in mice overexpressing CPT1A in tubular epithelial 
cells (TECs) (Supplemental Figure 1D). Obstructed kidneys from 
WT animals showed significant tubulo-interstitial architectural 
and histological changes 7 days after UUO, whereas the extent of 
tubular atrophy and dilatation was markedly reduced in kidneys 
with increased levels of CPT1A (Supplemental Figure 3A, left 
panel). Evaluation of renal lesions by light microscopy showed 
increased collagen deposition in the interstitial area after 7 days 
of the procedure in the obstructed kidneys compared with the 
contralateral ones in WT mice. A significant protective effect of 
CPT1A overexpression was observed by a reduction of 20%–40% 
in collagen deposition (Supplemental Figure 3A, right panel). As 
expected, circulating levels of BUN and creatinine were not differ-
ent between WT and CPT1A-KI mice after 7 days of UUO because 
of the remaining functional kidney (Supplemental Figure 3, B and 
C). A less dramatic but still significant decrease in FN and αSMA 
was also observed (Supplemental Figure 3, D and E).
To understand the mechanisms underlying the protective 
action of CPT1A on renal fibrosis, we performed expression anal-
ysis of whole kidney tissue from WT or CPT1A-KI mice subjected 
to FAN or 7 days of UUO. Expression of genes related to critical 
cellular functions for the initiation and perpetuation of tubular 
dysfunction and chronic tissue damage was analyzed by using spe-
cific TaqMan probes. A reduced expression for this subset of genes 
was observed in the FAN model. Quantitative real-time PCR-
based (qRT-PCR–based) quantification displayed lower expres-
sion of epithelial injury (Havcr1–KIM-1) and fibrotic markers (col-
lagens) in kidneys from CPT1A-KI mice (Figure 2F). These data 
were confirmed by mRNA quantitative analysis using SYBR green 
(Supplemental Figure 4A). A similar effect was observed in the 
UUO model (Supplemental Figure 3F and Supplemental Figure 
4B). These observations were also confirmed in the CKD mouse 
model of adenine-induced nephrotoxicity (ADN, Supplemental 
Figure 1E). CPT1A-KI mice showed a reduction in the expression 
of the crucial genes Col1a1, Fn1, and TGF-β involved in these cel-
lular mechanisms related to kidney fibrosis (Supplemental Figure 
5, A and B) as well as the same trend in the injury marker KIM-1 
(Supplemental Figure 5, C and D). Data collected from the 3 mod-
els of CKD in the CPT1A-KI mice strongly indicate that CPT1A is 
an enzyme that by itself has a crucial impact on the outcome of 
fibrosis, most likely because of its critical function in the facilita-
tion of FAO.
CPT1A overexpression prevents mitochondrial dysfunction and 
restores FAO in the fibrotic kidney. Renal mitochondrial abnormal-
ities and dysfunction are common features in the pathogenesis of 
different forms of renal disease (6). Cellular pathways promot-
ing kidney damage can compromise mitochondrial homeostasis, 
reflected in increased oxidative stress, apoptosis, microvascular 
loss, and fibrosis, all of which contribute to renal function deterio-
ration (7). Thus, we evaluated morphological alterations of mito-
chondria in cortical proximal tubules by transmission electron 
microscopy. Cells from tubular segments of healthy kidneys pre-
sented regular apical microvilli, intact basement membrane, and 
reverted when FAO-GOF was reinstated. Moreover, studies in 
patients with chronic renal failure showed that a reduction in the 
levels of CPT1A correlated with the degree of fibrosis. In addition, 
in a large cohort of diabetic patients with CKD, a specific profile of 
increased plasma acylcarnitines was found, reinforcing the critical 
metabolic derangement of FAO associated with CKD.
Results
Overexpression of tubular CPT1A results in protection against kidney 
fibrosis. To test the in vivo relevance of CPT1A and FAO for renal 
fibrosis, a mouse model with conditional, inducible expression of 
Cpt1a was engineered as described in Methods. To ensure renal 
epithelial tissue specificity, these animals were crossed with mice 
expressing an optimized reverse tetracycline-controlled transac-
tivator (rtTA2s-M2) driven by the paired box 8 (Pax8) promoter, 
hereafter termed Pax8-rtTA mice. Extrarenal expression of Pax8 
only occurs at the level of the thyroid without reported off-target 
effects (5). This results in tissue-specific expression of the Cpt1a 
gene bearing the tetracycline-responsive promoter element in the 
proximal and distal tubules and collecting duct, which is evident 
2 weeks after doxycycline administration (Figure 1, A and B and 
Supplemental Figure 1, A and B; supplemental material available 
online with this article; https://doi.org/10.1172/JCI140695DS1). 
We next characterized the renal-specific overexpression of 
CPT1A in this newly generated genetic mouse model based on 
the doxycycline-inducible transgenic system Tet-On. CPT1A-KI 
mice presented a 10-fold increase in the CPT1A mRNA level in 
whole kidney tissue compared with WT mice (Figure1C). This 
was accompanied by a marked augmentation of CPT1A protein 
expression in the kidney. Of note, no differences were observed 
when the liver tissue was analyzed (Figure 1, D and E). Tubules 
were labeled by lotus tetragonolobus lectin, a marker for prox-
imal tubules. Consistently, induced expression of CPT1A and 
GFP proteins was colocalized in tubule segments as evaluated by 
immunohistochemistry (Figure 1F). Importantly, overexpressed 
CPT1A presented a mitochondrial localization pattern, which was 
observed by double immunostaining by using the ATP synthase 
beta-subunit (βF1) as a marker (Figure 1G). To assess the magni-
tude of CPT1A overexpression on FAO, we analyzed the capacity 
of renal tissue to oxidize radiolabeled palmitate. Functionally, 
the increase in CPT1A protein in the renal epithelium increased 
the capacity of kidney tissue to oxidize 14C-palmitate as reflected 
in the levels of both 14C-palmitate–derived 14CO2 as well as in 
14C-palmitate–derived acid-soluble products (Figure 1H).
To evaluate the effect of the Cpt1a-knockin (CPT1A-KI) 
strategy on renal damage, we first used the FAN injury model 
(Supplemental Figure 1C, upper panel). Although we found no 
significant differences in the degree of tubular atrophy and dila-
tation (Supplemental Figure 2, A–C), fibrosis was markedly ame-
liorated in Pax8-rtTAtg/0 tetO-Cpt1atg/0 mice compared with WT 
mice (Figure 2A, left panel) and a significant reduction in the 
proportion of fibrosis as quantified by Sirius red was observed in 
the CPT1A-KI model (Figure 2A, right panel). Renal function was 
reduced in FAN-treated WT animals, as reflected by the increase 
in blood urea nitrogen (BUN) and creatinine, but this effect was 
blunted in mice overexpressing CPT1A (Figure 2, B and C). The 
protein expression of the classic profibrotic markers fibronec-
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Figure 1. Characterization of doxycycline-inducible Cpt1a gene overexpression in the transgenic mouse model for the inducible Cpt1a gene in renal 
epithelial cells. (A) Schematic depicting the strategy to generate mice with inducible renal tubular epithelial cell–specific overexpression of CPT1A. (B) PCR 
analysis of offspring genotypes from these crosses. Genomic DNA analysis by PCR for the Pax8-rtTA allele generates a 595-bp band (Supplemental Table 1). 
The GFP, exon, and FRT PCRs are described in Supplemental Figure 1A. (C) mRNA levels of the Cpt1a gene were determined by qRT-PCR in total kidney tissue 
of mice treated with doxycycline for 3 weeks. Data represent the mean ± SEM (n = 6 mice). **P < 0.05 compared with kidneys from WT mice. (D) Immuno-
blots depicting protein levels of CPT1A and GFP in kidneys and livers of 3 individual mice per group. β-actin was used for normalization purposes. (E) Bar 
graphs represent the mean ± SEM of fold changes corresponding to densitometric analyses (n = 6 mice). **P < 0.01 compared with kidneys from WT mice. 
(F) Representative images of double immunofluorescence staining with the proximal tubular marker lotus tetragonolobus lectin (LTL), GFP, DAPI (nuclei), 
and merge of all 3. (G) Staining with DAPI (nuclei), CPT1A, and the mitochondrial marker ATP synthase beta-subunit (βF1). All panels show immunofluores-
cence images of kidneys from WT and Pax8-CPT1A mice after doxycycline administration. Scale bar: 100 μm (F and G). (H) Radiolabeled palmitate-derived 
CO2 and acid-soluble products (ASP) were determined after incubation of 
14C-palmitate with kidney tissue from WT or Pax8-CPT1A mice after doxycycline 
treatment. Bar graphs represent the mean ± SEM (n = 4 mice). *P < 0.05 compared with kidneys from WT mice. Statistical significance between 2 indepen-
dent groups was determined using nonparametric 2-tailed Mann-Whitney U test; more than 2 groups were compared with Kruskal-Wallis test.
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there was a general downregulation trend in the expression of 
glycolysis-related genes, which was not recovered by CPT1A over-
expression (Figure 3E). By contrast, FAN-induced repression in 
mRNA levels of the peroxisomal/mitochondrial function–related 
genes Acox1, Cpt2, Lrpprc, Sdha, and Tfam was prevented in kid-
neys from CPT1A-KI mice (Figure 3F). In the UUO model, we 
found that the levels of the majority of the analyzed regulators of 
glucose utilization were not altered in obstructed kidneys com-
pared with contralateral ones. Only the increased expression of 
Ldh1 and Slc2a1 genes induced by UUO was prevented by CPT1A 
overexpression (Supplemental Figure 6F). Similarly, CPT1A GOF 
did not induce a major shift toward the expression of peroxisome/
mitochondrial-related genes in the contralateral kidneys (Supple-
mental Figure 6G).
To gain insight about quantitative metabolic changes at the 
cellular level, we examined the oxygen consumption rate (OCR) 
and extracellular acidification rate (ECAR) of primary TECs iso-
lated from the kidneys of CPT1A-KI mice (Figure 4A). We found 
that basal and maximum OCRs were markedly higher when pal-
mitic acid was supplied to TECs, indicating that TECs efficiently 
metabolized palmitate. The increase in OCR was sensitive to the 
CPT1 inhibitor etomoxir, confirming its specificity (Figure 4B). 
FAO-associated OCR was also higher in primary kidney epithelial 
cells isolated from CPT1A-KI compared with the ones isolated 
from WT mice. Cells treated with TGF-β1 had a lower baseline 
of oxygen consumption levels and showed a reduction in palmi-
tate-induced elevation in OCR, indicating a low activity of fatty 
acid metabolism. CPT1A overexpression prevented TGF-β1–
induced bioenergetic derangement (Figure 4C). Simultaneously, 
glycolytic function associated with palmitate consumption was 
determined by ECAR. Oligomycin-induced blockage of OXPHOS 
allows determination of maximum glycolytic capacity. We found 
that CPT1A overexpression promoted the inhibition of basal gly-
colytic function both in the presence and absence of TGF-β1 (Fig-
ure 4D). The increase in ATP levels related to CPT1A overexpres-
sion was also preserved under treatment with TGF-β1 (Figure 4E).
To confirm the metabolic functional consequences of CPT1A 
overexpression in the human setting, we examined OCR and 
ECAR in the human tubular epithelial cell line, HKC-8. Adenovi-
ruses carrying CPT1A (AdCPT1A) or adenovirus control (AdCon-
trol) as a negative control were used to infect HKC-8 cells. CPT1A 
protein levels were 4-fold higher in CPT1A-expressing HKC-8 
cells than in control cells (Supplemental Figure 7, A and B). Con-
sistent with our observations in epithelial cells from murine kid-
neys overexpressing CPT1A, HKC-8 cells transduced with CPT1A 
exhibited reduced TGF-β1–induced FAO inhibition (Supplemen-
tal Figure 7C) and suppression of glycolysis, as reflected by ECAR 
levels (Supplemental Figure 7D). As expected, we found that the 
FAO rate was 2-fold higher in AdCPT1A-expressing HKC-8 cells, 
as confirmed by measurement of 14C-palmitate–derived 14CO2 
(Supplemental Figure 7E). Consistently, CPT1A overexpression 
increased the fluorescence resonance energy transfer (FRET) sig-
nal of a specific ATP sensor and promoted a reduced decrement in 
the presence of TGF-β1 (Supplemental Figure 7F).
Depressed carbohydrate, amino acid, and lipid oxidative 
pathways have been described in patients and in animal models 
of CKD, leading to energy deprivation (6). AMPK is a highly con-
basal infoldings. Mitochondria were very abundant; most of them 
presented an elongated shape and were localized in the basolat-
eral part of the cells. They displayed a well-defined arrangement 
of well-preserved mitochondrial cisternae with a homogeneous 
inner matrix. In contrast, in the fatty acid–treated mice group, 
many epithelial cells were detached from the tubular basement 
membrane and showed disrupted basal infoldings. Mitochondrial 
structure was lost, and mitochondria presented a fragmented, 
small, and round appearance. Interestingly, most of these mor-
phological alterations in mitochondria as well as the reduction in 
mitochondrial mass induced by fatty acids were almost abrogated 
in renal epithelial cells overexpressing CPT1A (Figure 3A). CPT1A 
overexpression prevented the drop in mtDNA copy number in the 
3-day UUO (Supplemental Figure 6A) and FAN (Figure 3B) mod-
els of kidney damage. As expected, defective FAO was observed 
in fibrotic kidneys from WT mice. However, in the 3-day UUO, 
FAN, and ADN models, CPT1A overexpression counteracted 
this impairment, maintaining an FAO rate comparable to healthy 
kidneys (Figure 3C and Supplemental Figure 6, B and D). Closely 
related to the improvement in FAO by CPT1A, ATP content in 
whole kidney tissue increased from 50 to 80 μM/mg protein after 
CPT1A overexpression. In the 3-day UUO, FAN, and ADN models, 
CPT1A overexpression rescued the drop in ATP levels (Figure 3D 
and Supplemental Figure 6, C and E). These results suggest that 
appropriate levels of CPT1A and metabolic function are necessary 
and sufficient to preserve adequate mitochondrial architecture 
and morphology.
CPT1A GOF results in enhanced FAO-associated respiration of 
renal TECs even at the expense of glycolysis and AMPK activation. 
TECs use glucose for anaerobic glycolysis. Metabolic alterations of 
these cells during kidney fibrosis not only involve a defect in FAO 
but also in glucose oxidation (3). We found that in the FAN model, 
Figure 2. CPT1A overexpression prevents FAN-associated kidney func-
tion deterioration and experimental renal fibrosis. (A) Representative 
microphotographs from 1 mouse per group of H&E (upper panels) and 
Sirius red (lower panels) staining of kidneys from WT and Pax8-CPT1A 
mice subjected to FAN after doxycycline treatment (Dox). Scale bars: 
50 μm. Quantification of Sirius red staining represents the mean ± 
SEM, n = 6 mice. *P < 0.05 compared with FAN/C kidneys in WT mice, 
respectively. (B and C) Serum blood urea nitrogen (BUN) (B) and serum 
creatinine (C) levels of WT and Pax8-CPT1A mice subjected to FAN after 
doxycycline treatment. Data represent the mean ± SEM (n = 6 mice). *P 
< 0.05, **P < 0.01 compared with respective experimental control (CT) 
condition; #P < 0.05 compared with WT mice with the same experimen-
tal condition. (D) Immunoblots depicting fibronectin (FN), carnitine 
palmitoyltransferase 1A (CPT1A), GFP, and alpha-smooth muscle actin 
(α-SMA) protein levels in kidneys from control (CT) and FA-treated (FAN) 
WT and Pax8-CPT1A mice after doxycycline induction. (E) Bar graphs 
represent the mean ± SEM of fold changes corresponding to densito-
metric analyses (n = 6 mice). (F) mRNA levels of fibrosis-associated  
genes were determined by qRT-PCR using TaqMan qPCR probes in 
kidneys from CT and FAN WT and Pax8-CPT1A mice after doxycycline 
induction. Bar graphs represent the mean ± SEM of fold changes (n = 6 
mice). (E and F) *P < 0.05, **P < 0.01 compared with their corresponding 
CT kidneys; #P < 0.05, ##P < 0.01 compared with kidneys from WT mice 
with the same experimental condition. Statistical significance between 
2 independent groups was determined using nonparametric 2-tailed 
Mann-Whitney U test; more than 2 groups were compared with Kruskal- 
Wallis test. For gene nomenclature, see Supplemental Table 4.
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Figure 3. CPT1A prevents impaired mitochondrial morphology and FAO defect in FAN-induced kidney fibrosis. (A) Representative electron microscopy 
images of cortical proximal tubules from control and Pax8-CPT1A mice subjected to FAN after doxycycline induction. Scale bars: 10 μm (upper panels),  
100 nm (lower panels). (B) Mitochondrial DNA copy number (mtDNA) was determined in kidneys of WT and Pax8-CPT1A mice in the FAN model. Bar graphs 
represent the mean ± SEM of fold changes (n = 6 mice). **P < 0.01 compared with their corresponding control (CT) kidneys; ##P < 0.05 compared with 
kidneys from WT mice with the same experimental condition. (C) Radiolabeled palmitate-derived CO2 was determined after incubation of 14C-palmitate 
with kidney tissue from WT and Pax8-CPT1A mice in the FAN model after doxycycline induction. (D) ATP levels in total kidney tissue determined in mice 
subjected to FAN model. (C and D) Bar graphs represent the mean ± SEM (n = 4 mice). *P < 0.05, **P < 0.01 compared with their corresponding CT kidneys; 
#P < 0.05 compared with kidneys from WT mice with the same experimental condition. (E and F) mRNA levels of glucose utilization–associated genes (E) 
and peroxisomal/mitochondrial function–associated genes (F) were determined by qRT-PCR using TaqMan qPCR probes in kidneys from CT and FA-treated 
(FAN) WT and Pax8-CPT1A mice after doxycycline induction. (E and F) Bar graphs represent the mean ± SEM of fold changes (n = 6 mice). *P < 0.05, **P 
< 0.01 compared with their corresponding CT kidneys; #P < 0.05, ##P < 0.01 compared with kidneys from WT mice with the same experimental condition. 
Statistical significance between 2 independent groups was determined using nonparametric 2-tailed Kruskal-Wallis test. For detailed gene nomenclature, 
see Supplemental Table 4.
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served sensor of intracellular metabolic status and plays a critical 
role in systemic energy homeostasis (8). To determine whether 
FAO-GOF in the kidneys of CPT1A-KI mice was associated with 
changes in AMPK activation as a consequence of increased ATP 
levels, phosphorylation of AMPK was analyzed by immunoblot. In 
the FAN model, obstructed kidneys presented increased AMPK 
phosphorylation protein levels compared with contralateral kid-
neys. Importantly, increasing CPT1A levels attenuated AMPK 
phosphorylation in fibrotic kidneys in the FAN model (Supplemen-
tal Figure 8, A and B). The levels of phosphorylated acetyl-CoA 
carboxylase, directly dependent on AMPK, changed accordingly. 
Similar data were obtained in the UUO and ADN models (Supple-
mental Figure 8, C–F). Overall, we found that increased FAO asso-
ciated with overexpression of CPT1A improved mitochondrial res-
piration in the context of reduced glycolysis. Moreover, it is likely 
that the enhancement of ATP production related to FAO reins in 
AMPK activation triggered by chronic kidney damage, indepen-
dent of the model employed.
Overexpression of CPT1A modifies the cellular inflammatory pro-
file and abrogates TGF-β–associated epithelial cell damage. Studies in 
patients and in animal models show a strong correlation between 
infiltrated macrophage polarization and the extent of fibrosis 
(9). In the FAN model, we found that overexpression of CPT1A 
correlated with a decreasing trend in macrophage influx (Fig-
ure 5, A and B), and flow cytometry analysis revealed a reduced 
proportion of the renal proinflammatory M1 subpopulation (Fig-
ure 5, C and D). In the UUO (Supplemental Figure 9, A and B) 
and ADN (Supplemental Figure 5, E and F) models, the CPT1A- 
induced decrement in macrophage influx was also confirmed. By 
contrast, the macrophage subpopulation positive for CD86 (M1) 
was higher than that for CD206 (M2) in fibrotic kidneys 3 and 7 
days after UUO, whereas CPT1A overexpression did not affect this 
shift (Supplemental Figure 9, C–F). However, the M2 macrophage 
subpopulation was increased in fibrotic kidneys from CPT1A-KI 
mice compared with the WT ones after 7 days of UUO (Supple-
mental Figure 9, E and F). Infiltration of the macrophage subpop-
ulation positive for both CD86 and CD206 (M1/M2) observed in 
obstructed kidneys from WT mice 3 or 7 days after UUO was also 
enhanced by CPT1A overexpression (Supplemental Figure 9, D 
and F). In addition, the abundance of this M1 subpopulation was 
lower in FAN-induced fibrotic kidneys than in UUO-associated 
ones (Figure 5D and Supplemental Figure 9, D and F). These data 
suggest that the changes in the degree of macrophage infiltration 
and relative contributions of macrophage subpopulations are 
dependent on the model of kidney injury.
Inflammation is a major hallmark of renal fibrosis, especially 
in the early stages (9). Consistently, kidney infiltration by CD3+ T 
lymphocytes after FAN was reduced in CPT1A-KI mice compared 
with WT mice (Supplemental Figure 2, D and E). Thus, we ana-
lyzed the profile of prototypical molecules related to inflamma-
tion in the kidneys of mice overexpressing CPT1A in the context 
of renal damage. In the FAN model, we found a lower expression 
of inflammation-related markers, including the cytokines IL-1b, 
IL-6, and Tnf-α (Figure 5E), in contrast to the findings in the 7-day 
UUO model (Supplemental Figure 10C). Consistently, cells from 
kidneys of mice overexpressing CPT1A presented a reduced pop-
ulation of damaged epithelial cells (CD45– EpCAM+ CD24+; ref. 
10) compared with those of WT mice in both the FAN and 7-day 
UUO models (Figure 6, A and B and Supplemental Figure 10, A 
and B). In the FAN model, the levels of 3 necroptosis markers, 
receptor-interacting serine/threonine-protein kinase (RIPK1), 
mixed lineage kinase domain-like pseudokinase (MLKL), and 
phosphorylated RIPK-3, were significantly blunted in the presence 
of CPT1A overexpression (Figure 6, C–E). Moreover, there was 
also a reduced expression of the apoptotic markers Apaf1, Bax, 
and Bcl2 (Figure 6F). A similar pattern regarding the expression 
of apoptotic markers was observed in the 7-day UUO model (Sup-
plemental Figure 10D).
Epithelial cell dedifferentiation is a process associated with 
the transformation of a terminal cellular phenotype into one with 
relatively higher potential of differentiation into more than one 
cell type (11). This dedifferentiation is characterized by the loss 
of epithelial markers and acquisition of mesenchymal features, a 
process known as epithelial-mesenchymal transition (EMT, ref. 
12), the role of which in kidney fibrosis remains controversial. We 
studied the expression of E-cadherin, whose loss is considered 
a representative feature of EMT, in the setting of CPT1A over-
expression and found no significant differences in renal tubu-
lar expression in any of the 3 models employed (Supplemental 
Figure 11A). A similar pattern was observed when further EMT- 
associated markers were analyzed in the FAN model. Only the 
EMT-associated increased expression of Snail was prevented in 
the kidneys of CPT1A-KI mice (Supplemental Figure 11B). We 
also tested whether enhancing renal epithelial FAO had a pro-
tective role in TGF-β–induced transformation of epithelial cells 
into a cellular fibrotic phenotype. Primary kidney epithelial cells 
isolated from CPT1A-KI mice and treated with TGF-β1 for 48 
hours showed a marked reduction in the increase of these EMT- 
associated markers compared with the cells isolated from WT 
mice (Supplemental Figure 11C). Consistently, HKC-8 cells trans-
duced with CPT1A exhibited a lower expression of collagen (Sup-
plemental Figure 11D) and fibronectin (Supplemental Figure 11E). 
This set of data indicate that the protective action of CPT1A in 
kidney fibrosis operates, at least in part, through the attenuation 
of TGF-β1–induced TEC transformation.
Overexpression of CPT1A after damage markedly attenuates 
the fibrotic phenotype. To investigate whether restoration of 
FAO-GOF after injury could also protect from kidney damage, 
we started doxycycline administration after fatty acid injection 
and confirmed that CPT1A levels increased gradually in the 
CPT1A-KI mice (Supplemental Figure 12, A–C). We observed 
that the fibrotic area and renal function impairment were sig-
nificantly reduced in the CPT1A-KI model (Figure 7, A–C). The 
expression of the profibrotic markers Col1a1 and Fn1 was also 
significantly reduced in the CPT1A-KI mice (Figure 7D). TECs 
from CPT1A-KI mice also exhibited a more favorable mitochon-
drial bioenergetic profile after damage, which was reflected 
by a higher ATP production rate and basal and maximum OCRs 
(Figure 7, E and F). This data reinforces the potential of FAO-
GOF to combat kidney fibrosis even when renal damage has 
already been initiated.
An increase in plasma acylcarnitines and a reduction of CPT1A 
levels is present in patients with CKD. To explore the importance of 
FAO in a clinical context, we analyzed a cohort of 686 patients 
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Figure 4. CPT1A overexpression prevents TGF-β1–induced FAO impairment. (A) Bright field or GFP immunofluorescence images of primary kidney epithelial 
cells (TECs) isolated from kidneys of WT and Pax8-CPT1A mice. Scale bar: 20 μm. (B) Oxygen consumption rate (OCR) of TECs from WT mice was measured 
with a Seahorse XF24 Extracellular Flux Analyzer. Where indicated, cells were pretreated with palmitate-BSA FAO substrate (200 μM) or the CPT1 inhibitor 
etomoxir (Eto, 400 μM). Oligomycin (1 μM), FCCP (3 μM), and a combination of antimycin A (1 μM) and rotenone (1 μM) (AA/Rot) were injected sequentially 
at the time points indicated. Each data point represents the mean ± SEM of 4 independent experiments, each performed in triplicate. (C) OCR of TECs from 
WT and Pax8-CPT1A mice was measured with a Seahorse XF24 Extracellular Flux Analyzer. Bar graphs (right panel) show the rates of OCR associated with 
basal, proton-leak, ATP-linked, maximum, reserve capacity, and nonmitochondrial respiratory statuses. *P < 0.05 compared with their corresponding control 
(CT) TECs; #P < 0.05 compared with TECs from WT mice with the same experimental condition. (D) Extracellular acidification rate (ECAR) of cells treated as in 
A. Each data point represents the mean ± SEM of 4 independent experiments, each performed in triplicate. (E) ATP levels of TECs from WT and Pax8-CPT1A 
mice. Bar graphs represent the mean ± SEM (n = 4 mice per group). #P < 0.05 compared with kidneys from WT mice with the same experimental condition. 
Statistical significance between 2 independent groups was determined using nonparametric 2-tailed Kruskal-Wallis test.
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Figure 5. Overexpression of CPT1A reduces M1 macrophage infiltration in the FAN model. (A) Representative micrographs of 1 mouse per group showing 
the expression of F4/80 in kidney sections of mice treated as described above. Scale bar: 50 μm. (B) Bar graph represents the quantification of the per-
centage of F4/80+ stained area in FA-treated mouse kidneys (FAN). Bar graphs represent the mean ± SEM, n = 4 mice. (C) Representative multiparameter 
flow cytometry dot plots showing the expression of CD45 and F4/80 in kidney cells from WT and Pax8-CPT1A mice subjected to FAN after doxycycline 
induction (upper panels) (1 mouse per group is represented). CD86 and CD206 were used to determine the proportion of M1 and M2 macrophage subpop-
ulations, respectively, in the total macrophage population (F4/80+, CD45+) (lower panels). Numbers in quadrants indicate cell proportions in percentage 
of cells that express both markers. (D) Bar graph represents the percentage of kidney cells expressing CD86 (M1), CD206 (M2), or both (M1/M2) markers. 
Data represent mean ± SEM (n = 4 mice). ***P < 0.001 compared with M1 subpopulation in damaged kidneys from WT mice; #P < 0.05 compared with 
corresponding cell subpopulation in damaged kidneys from WT mice. (E) mRNA levels of inflammation-associated genes were determined by qRT-PCR 
using TaqMan qPCR probes in kidneys from control (CT) and FA-treated (FAN) WT and Pax8-CPT1A mice after doxycycline induction. Bar graphs represent 
the mean ± SEM of fold changes (n = 6 mice). *P < 0.05, **P < 0.01 compared with their corresponding CT kidneys; #P < 0.05 compared with kidneys from 
WT mice with the same experimental condition. Statistical significance between 2 independent groups was determined using nonparametric 2-tailed 
Mann-Whitney U test; more than 2 groups were compared with Kruskal-Wallis test. For detailed gene nomenclature, see Supplemental Table 4.
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CoA chains into the mitochondrial matrix with the concourse of 
L-carnitine (15). To date, no drugs are available to specifically acti-
vate CPT1 and hence, pharmacological studies are not devoid of 
limitations. Homozygous CPT1A deficiency is lethal in the mouse 
(16); tissue-specific CPT1A-KO models for the endothelium (17), 
pancreatic α cells (18), and intestinal stem cells (19) have been gen-
erated. None of these studies addressed potential consequences 
on organ fibrosis. The FAO-GOF genetic model herein described 
is likely one of the first direct demonstrations of the potential of 
this strategy to treat kidney fibrosis. The study was performed in 
heterozygous mice in an attempt to avoid nonphysiological scenar-
ios due to CPT1A overdosing (20). Mitigation of renal fibrogen-
esis was reflected in a reduction of fibrotic markers, histological 
improvement, and amelioration of renal function. Slight differ-
ences in the magnitude of changes are most likely due to variation 
in the intensity of the inflammatory or fibrotic components among 
models. Although no experimental model recapitulated with close 
fidelity human CKD, the significant correlation between advanced 
kidney disease and 2 signatures of FAO reduction (increased acyl-
carnitines and low CPT1A) in 2 large patient cohorts attests to the 
clinical relevance of an FAO-related major metabolic disturbance 
in human CKD (21). Adjustment for age, sex, diabetic state, and 
albumin/creatinine ratio indicates that renal function was likely 
the variable accounting for these differences, even though the con-
tribution of other tissues, such as adipose, cannot be completely 
excluded. The fact that we could not evaluate levels of CPT1A and 
acylcarnitines simultaneously in any of the 2 cohorts poses some 
limitations for a clear-cut interpretation. We found correlation 
between GFR and short- and medium- but not long-chain acyl-
carnitine levels, as could be initially expected. In a detailed study, 
Afshinnia et al. found higher plasma abundance of long-chain 
free fatty acids coupled with a significantly lower long-to-inter-
mediate acylcarnitine ratio (a marker of impaired β-oxidation) 
in severe stages of CKD, but CPT1A levels were not determined 
(21). Increased levels of short and middle acylcarnitines in the 
diabetic cohort with CKD may be explained by alterations in the 
expression or activity of FAO-related enzymes, including CPT1A 
(3), as accumulation of short- and middle-chain acylcarnitines 
may result from incomplete FAO of long-chain acylcarnitines (22). 
Further, the systemic clearance of acylcarnitines may be dif-
ferentially impaired in this population, also affecting their bio-
distribution (23, 24).
The high energetic demand of renal TECs, required for their 
performance of multiple functions related to the homeostasis of 
the internal milieu, dictates their dependence on intact mitochon-
drial function. We showed that FAO-GOF, attained by overex-
pressing tubular CPT1A (in both animals and cells), restored mito-
chondrial mass and architecture, enhanced OCR, and increased 
ATP production in conditions of renal damage. This appeared to 
occur at the expense of glycolysis because ECAR was significantly 
lower under conditions of CPT1A overexpression. The reciprocal 
regulation between FAO and glycolysis, the Randle cycle (25), has 
been demonstrated in the muscle and heart; our data showed that 
it also takes place in renal tubular cells. Alternatively, it is possible 
that TECs are consuming lactate as the main fuel for gluconeo-
genesis, a process in which the kidney plays an essential role (26). 
The fundamental question as to whether metabolism dictates 
with CKD and diabetes pertaining to the PREDIMED study 
(ref. 13, see Supplemental Table 7 for details). In patients whose 
renal function parameters were available (n = 686), we deter-
mined the levels of acylcarnitines. We found inverse correla-
tion between glomerular filtration rate (GFR) and short-chain 
(c2-c7) and medium-chain (c8-c14) acylcarnitine levels (Figure 
8, A and B and Supplemental Tables 8 and 9) in patients with a 
GFR under 60 mL/min. Thus, CKD patients with a higher GFR 
showed less accumulation of short- and medium-chain acylcar-
nitines (Figure 8, D, E, and G), with no correlation in the case 
of long-chain (c16-c26) acylcarnitines (Figure 8, C and F). In a 
different cohort of CKD patients (see Supplemental Table 10 for 
details), we found a positive correlation between tubule CPT1A 
expression levels and eGFR (Figure 8, H and I) in an RNA-Seq 
study from different pathological backgrounds. The degree of 
fibrosis also correlated significantly with declining CPT1A levels 
(Figure 8J). The increase in the levels of acylcarnitines and the 
reduction in the levels of the limiting-step enzyme responsible 
for their metabolism (CPT1A) most likely reflect a decreased FAO 
capacity associated with CKD. Thus, these results underscore 
the relevance of reduced FAO in CKD and support the impor-
tance of its GOF to combat kidney fibrosis, as demonstrated 
in our experimental model.
Discussion
Kidney fibrosis is critically linked to metabolic failure in TECs 
(14). We demonstrated that genetic FAO-GOF was sufficient to 
provide significant mitigation of fibrosis development in 3 exper-
imental models of chronic kidney damage. Moreover, FAO-GOF 
was also therapeutically effective when reinstated after kidney 
damage. Although FAO is a complex process depending on sev-
eral biochemical steps and enzymatic systems, CPT1A is rate- 
limiting because of its key role for shuttling medium and long acyl 
Figure 6. CPT1A overexpression reduces epithelial cell damage in the 
FAN model. (A) Representative flow cytometry dot plots from obstructed 
kidneys of WT and Pax8-CPT1A mice subjected to FAN after doxycycline 
treatment. Cells were gated for CD45 negative/epithelial cell adhesion 
molecule (EpCAM) positive (upper panels) and selected for the presence 
of CD24 (lower panels). Numbers in quadrants indicate cell proportions. 
(B) Bar graphs show the percentage of kidney cells positive for CD24. Data 
represent the mean ± SEM (n = 4 mice). *P < 0.05 compared with their 
corresponding control (CT) kidneys; #P < 0.05 compared with damaged 
kidneys in WT mice. (C and D) Representative immunoblots and densitom-
etries corresponding to CPT1A and phosphorylated RIPK3 protein levels 
in kidneys as in A (n = 3 mice). *P < 0.05, **P < 0.01 compared with their 
corresponding CT kidneys; #P < 0.05, ##P < 0.01 compared with kidneys 
from WT mice with the same experimental condition. (E) mRNA levels of 
RIPK1, RIPK3, and MLKL were determined by qRT-PCR in kidneys as in A. 
Bar graphs represent the mean ± SEM of fold changes (n = 6 mice). ***P < 
0.001 compared with their corresponding CT kidneys; ##P < 0.01 compared 
with kidneys from WT mice with the same experimental condition. (F) 
mRNA levels of apoptosis-associated genes were determined by qRT-PCR 
using TaqMan qPCR probes in kidneys from CT and FA-treated (FAN) WT 
and Pax8-CPT1A mice after doxycycline induction. Bar graphs represent the 
mean ± SEM of fold changes (n = 6 mice). *P < 0.05, **P < 0.01 compared 
with their CT kidneys; ##P < 0.05 compared with kidneys from WT mice 
with the same experimental condition. Statistical significance between 2 
independent groups was determined using nonparametric 2-tailed Krus-
kal-Wallis test. For detailed gene nomenclature, see Supplemental Table 4.
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of the Cpt1a gene were cloned into a unique EcoRI site of pBS31 vector 
(OriGene Technologies). This vector contains the phosphoglycerate 
kinase (PGK) promoter followed by an ATG start codon and an FRT 
recombination site, a splice acceptor-double polyA cassette, the tetra-
cycline operator with a CMV minimal promoter, and an SV40 polyA 
signal, assembled in Bluescript. By using FRT/flippase-mediated 
recombination system (27, 28), the CPT1A transgene was targeted 
into the downstream region of the collagen 1a1 (Col1a1) locus of KH2 
ES cells containing an frt-flanked PGK-neomycin-resistance gene 
followed by a promoterless, ATG-less hygromycin-resistance gene. 
These cells also contained the M2-rtTA under control of the endog-
enous ROSA26 promoter (29). For gene targeting, 50 μg pBS31 vector 
and 25 μg vector encoding the flippase (pCAGGS-FLP, ref. 30) were 
co-electroporated with 1.5 × 107 KH2 ES cells at 400 V and 125 μF 
using 2 pulses in a Gene Pulser II (Bio-Rad). Recombination between 
FRT sites such that the entire plasmid is inserted within the PGK 
promoter and the ATG initiation codon upstream and in frame with 
the hygromycin resistance gene was used to select correctly targeted 
cells. ES cells were treated with 140 μg/mL hygromycin B (Carl Roth) 
after 48 hours of electroporation to select clones that had undergone 
site-specific recombination and individual clones were picked after 8 
to 14 days (31). Individual ES clones were tested in vitro by treating 
them with 1 μg/mL doxycycline (Sigma-Aldrich) in the culture media 
for 4 days. Then, GFP was measured in a FACSCanto II cytometer 
(BD Biosciences) to assess the electroporation efficiency, and cells 
expressing GFP were sorted.
Doxycycline induction. To induce CPT1A expression, 8-week-
old Pax8-rtTAtg/0 tetO-Cpt1atg/0 mice and corresponding Pax8-rt-
TA0/0 tetO-Cpt1atg/0 (WT) mice were fed with doxycycline (Sigma- 
Aldrich) at concentrations of 1 mg/mL via drinking water for 3 
weeks. Mice were housed in colony cages with a 12-hour light/12-
hour dark cycle in a temperature- and humidity-controlled environ-
ment with free access to water.
Genotyping. Mice were genotyped by PCR using DNA extracted 
from tail biopsies and the primers listed in Supplemental Table 1. DNA 
extraction was performed by using the AccuStart II Mouse Genotyp-
ing Kit (Quantabio) according to the manufacturer’s instructions.
Cell lines and culture conditions. Human proximal TECs (HKC-8) 
were cultured in DMEM/F12 1:1 (v/v) (Corning) supplemented with 
15 mM HEPES, 5% (vol/vol) FBS (HyClone Laboratories), 1× insu-
lin-transferrin-selenium (ITS) (Gibco), 0.5 μg/mL hydrocortisone 
(Sigma-Aldrich), 50 units/mL penicillin, and 50 μg/mL streptomycin 
(Gibco). This cell line was provided in-house. HEK293A cells obtained 
from ATCC were cultured in DMEM supplemented with 10% (v/v) 
FBS (HyClone Laboratories) and 1% penicillin/streptomycin (Gibco). 
All cells were cultured at 37°C and 5% CO2 and treated with trypsin 
every 5 days for subculturing. Treatments with human recombinant 
10 ng/mL TGF-β1 (R&D Systems) were performed after serum-free 
starvation for 12 hours.
Isolation of primary kidney epithelial cells. Kidneys from CPT1A-KI 
and WT mice (3- to 5-week-old males) were collected after euthani-
zation and minced into pieces of approximately 1 mm3. These pieces 
were digested with 10 mL HBSS containing 2 mg/mL collagenase I 
(Thermo Fisher Scientific) for 30 minutes at 37°C with gentle stirring, 
and supernatants were sieved through a 100 μm nylon mesh. After 
centrifugation for 10 minutes at 300 g, the pellet was resuspended in 
sterile red blood cell lysis buffer (8.26 g NH4Cl, 1 g KHCO3, and 0.037 
phenotype is in part answered here, as our data indicate that an 
increased capacity of the TEC to meet its energy challenges is able 
to both prevent and revert kidney fibrosis. Thus, efforts directed at 
enhancing FAO in the early stages of fibrosis should very likely pay 
off to combat human CKD.
Methods
Generation of a transgenic mouse model for the inducible Cpt1a gene. 
Generation of an inducible conditional transgenic mouse model for 
Cpt1a overexpression in the renal epithelium was based on a sec-
ond generation Tet-On system with site-specific recombination in 
embryonic stem (ES) cells (27, 28). Mice harboring the transgene of 
the Cpt1a gene under the control of the tetracycline-responsive pro-
moter element (tetO-Cpt1a mice) were generated in the transgenic 
mice core unit from the National Cancer Research Center (CNIO; 
Madrid, Spain). Mice were generated by diploid blastocyst injection. 
Blastocysts were harvested at 3.5 days after coitum from C57/BL6-J 
strain females. Between 10 and 15 KH2 ES cells were injected per blas-
tocyst. Approximately 30 injected blastocysts were transferred into 
pseudopregnant CD1 strain–recipient females (transgenic mice core 
unit, CNIO). Chimeras from the litter with a high percentage of agouti 
coat color (>80%) were then crossed with C57/BL6-J mice to evaluate 
germline transmission. Next, these mice were crossed with mice pro-
viding renal epithelial tissue specificity, Pax8-rtTA (The Jackson Labo-
ratory). Male tetO-Cpt1atg/0 mice were bred with Pax8-rtTAtg/0 female 
mice to generate double heterozygous Pax8-rtTAtg/0 tetO-Cpt1atg/0 
mice and their control littermates in a B6N 129Sv mixed genetic back-
ground. Extrarenal expression only occurs at the level of the thyroid, 
and this fact does not interfere with any kidney phenotype (5).
Molecular cloning and gene targeting in ES cells. The CPT1A trans-
gene containing the 5′UTR of the Cpt1a gene, the Cpt1a open read-
ing frame (ORF) (GenBank accession number NM_013495.2), the 2A 
self-cleaving peptide (P2A), the gene encoding for GFP, and the 3′UTR 
Figure 7. CPT1A upregulation after FA-induced renal disease mitigates 
FAN-associated kidney function deterioration, renal fibrosis, and FAO 
defects. (A) Representative microphotographs of H&E (upper panels) and 
Sirius red (lower panels) staining of kidneys from WT and Pax8-CPT1A 
mice subjected to FAN prior to doxycycline (Dox) (Supplemental figure 
12A). Scale bars: 50 μm. Quantification of Sirius red staining represents 
the mean ± SEM, n = 6 mice. **P < 0.05 compared with FAN kidneys in 
WT mice. (B and C) Serum BUN (B) and creatinine (C) levels of WT and 
Pax8-CPT1A mice subjected to FAN as in A. Data represent the mean ± 
SEM (n = 6 mice). *P < 0.05, ***P < 0.001 compared with respective  
control (CT) condition; #P < 0.05 compared with WT mice with the same 
condition. (D) mRNA levels of α-SMA, Col1α1, FN, CPT1A, and Ppargc1a 
determined by qRT-PCR in kidneys of WT and Pax8-CPT1A mice subjected 
to FAN as in A. Bar graphs represent the mean ± SEM of fold changes  
(n = 6 mice). *P < 0.05, **P < 0.01 compared with corresponding CT 
kidneys; #P < 0.05, ##P < 0.01 compared with kidneys from WT mice with 
the same condition. (E and F) ATP production rate of TECs from WT and 
Pax8-CPT1A mice subjected to FAN as in A. ***P < 0.001 compared with 
TECs from WT mice with the same condition. (F) Oxygen consumption 
rate (OCR) of TECs from WT and Pax8-CPT1A mice subjected to FAN as in 
A. Bar graphs (right panel) show the rates of OCR as in Figure 4C. **P < 
0.01 compared with their corresponding control (CT) TECs; #P < 0.05 and 
##P < 0.01 compared with TECs from WT mice with the same condition. 
Statistical significance between 2 independent groups was determined 
using nonparametric 2-tailed Mann-Whitney U test; more than 2 groups 
were compared with Kruskal-Wallis test.
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Figure 8. Plasma acylcarnitines and CPT1A levels in patients with CKD. (A–C) Correlation between baseline GFR values and plasma short-chain acyl-
carnitines (A), medium-chain acylcarnitines (B), and long-chain acylcarnitines (C) score in CKD patients with GFR less than 60 mL/min. (D–F) Correlation 
between baseline GFR values and plasma short-chain acylcarnitines (D), medium-chain acylcarnitines (E), and long-chain acylcarnitines (F) score in CKD 
patients with GFR greater than or equal to 60 mL/min. (G) Baseline acyl-carnitine levels by CKD stage. P values for the comparison of acylcarnitine levels 
between participants with GFR lower than 60 mL/min versus GFR greater than or equal to 60 mL/min. (H) CPT1A levels in renal biopsies from control and 
patients with CKD, diabetic kidney disease (DKD), diabetes mellitus (DM), or hypertension (HTN). (I and J) Correlation between CPT1A kidney levels and 
eGFR (I) or fibrosis score (J). For box-and-whisker plots (G and H), within each box, horizontal white lines denote median values; boxes extend from the 25th 
to the 75th percentile of each group’s distribution of values; vertical extending lines denote adjacent values (i.e., the most extreme values within 1.5 IQR 
of the 25th and 75th percentile of each group); dots denote observations outside the range of adjacent values. (A–G) χ2 and Student’s t test were used to 
compare categorical and quantitative variables, respectively. (H) ANOVA test was used to assess the significance across different disease groups. Cor.test 
function in R was used to obtain the Pearson’s correlation and the corresponding P values.
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procedure section. Then, cells were incubated in 500 μL of media con-
taining 0.3% BSA/100 μM palmitate/0.4 μCi/mL 14C-palmitate at 37 
°C for 3 hours. Each sample was assayed in triplicate. The reaction was 
stopped by the addition of 200 μL of 1 M perchloric acid. The rate of 
palmitate oxidation was measured as released 14CO2 trapped in a fil-
ter paper disk with 20 μL of 1 M NaOH in the top of sealed vials. The 
remaining acid solution for each sample was centrifuged at 14,000 g 
for 10 minutes at 4°C and 400 μL of supernatant was added to scintilla-
tion vials for the quantification of 14C-palmitate–derived acid-soluble 
metabolites. 14C products were counted in an LS6500 liquid scintilla-
tion counter (Beckman Coulter). Scintillation values were converted 
to mmol 14CO2 or acid-soluble metabolites by multiplying the specific 
activity and normalized to the protein content.
TaqMan gene expression assay. TaqMan array plates (Thermo Fisher 
Scientific) were selected as the platform for gene expression profiling. 
This panel consisted of a total of 43 unique TaqMan probes specific for 
mouse genes related to fibrosis, apoptosis, mitochondrial metabolism, 
glucose utilization, and inflammation listed in Supplemental Table 4. 
RNA extraction from kidney samples was performed as described in 
the RNA extraction procedure section. Next, 2 μg of total RNA was 
subjected to reverse transcription using the High-Capacity cDNA 
Reverse Transcription Kit (Thermo Fisher Scientific) according to the 
manufacturer’s instructions. PCR amplification was performed using 
TaqMan master (Thermo Fisher Scientific) with the Roche Light-
Cycler 480 Real-Time PCR system (AB7900HT). This procedure was 
performed in the Genomic Facility of the Fundación Parque Científico 
de Madrid. The ABI TaqMan SDS v2.4 software was utilized to obtain 
Cq values (Cq) for each gene. The Cq data were analyzed with Stat-
Miner 4.2.8 software (Integromics). The ΔCt value was calculated by 
normalizing Ct values to the endogenous housekeeping gene 18S. Rel-
ative mRNA expression was determined using the 2−ΔΔCt method (32). 
Fold changes were normalized to values of the control condition.
Mitochondrial copy number determination. Genomic DNA was 
extracted from mouse kidneys using the DNeasy Blood & Tissue Kit 
(Qiagen) according to the manufacturer’s instructions. Mitochondrial 
abundance was determined with the Mouse Mitochondrial DNA Copy 
Number Assay Kit (Detroit R&D). Relative mtDNA copy number was 
presented as the mtDNA to nuclear DNA ratio.
Assessment of kidney function. Animal kidney function was deter-
mined by analyzing the indicators serum creatinine and BUN by using 
the QuantiChrom TM Creatinine Assay Kit (BioAssay Systems) and 
the BUN Colorimetric Detection Kit (Arbor Assays), respectively, 
according to the manufacturers’ instructions. In the case of the rever-
sion experiments (Figure 7), serum creatinine was measured by capil-
lary electrophoresis (Agilent 7100) coupled to TOF mass spectrometry 
(Agilent 6224) (34, 35). A calibration curve was used for quantification 
with creatinine; methionine sulphone was the internal standard.
Measurement of ATP level. ATP content in kidney tissue, HKC-8, 
and primary kidney epithelial cells was measured by using the ATP 
colorimetric/fluorometric assay kit (BioVision Inc.) according to the 
manufacturer’s instructions. Data were normalized for total protein 
content. In HKC-8 cells, relative ATP content was also assessed with 
the FRET Clover-mApple ATP sensor (36, 37). Cells were seeded in 
12-well dishes to reach a confluence of 70% and transfected with 1.5 
μg vector/well using Lipofectamine 2000 (Invitrogen). Then, cells 
were infected with CPT1A adenoviruses as described in the adeno-
virus-mediated CPT1A overexpression procedure section and FRET 
g EDTA per 1 L ddH2O) and seeded in 10 cm culture dishes. Cells 
were cultured in RPMI 1640 (Corning) supplemented with 10% FBS 
(HyClone Laboratories), 20 ng/mL EGF (Sigma-Aldrich), 20 ng/mL 
bFGF (Sigma-Aldrich), 50 units/mL penicillin, and 50 μg/mL strep-
tomycin (Gibco) at 37°C and 5% CO2. Cells were used between days 7 
and 10 of culture.
Immunoblot. Cells or a quarter piece of each kidney sample were 
homogenized and lysed in 100/300 μL RIPA lysis buffer containing 
150 mM NaCl, 0.1% SDS, 1% sodium deoxycholate, 1% NP-40, and 
25 mM Tris-HCl pH 7.6 in the presence of cOmplete Protease Inhib-
itor Cocktail (Roche Diagnostics) and phosphatase inhibitor (Sigma- 
Aldrich). Samples were clarified by centrifugation at 10,000 g for 
15 minutes at 4°C. Protein concentrations were determined by the 
BCA Protein Assay Kit (Thermo Fisher Scientific) and measured in 
GloMax-Multi Detection system (Promega). Equal amounts of pro-
tein (10–50 μg) from the total extract were separated on 8%–10% 
SDS-polyacrylamide gels and transferred onto nitrocellulose blotting 
membranes (GE Healthcare) at 12 V for 20 minutes in a semidry Trans-
Blot Turbo system (Bio-Rad). Membranes were blocked by incubation 
for 1 hour with 5% nonfat milk in PBS containing 0.5% Tween-20 and 
blotted overnight with the specific antibodies listed in Supplemental 
Table 2. After incubation with IRDye 800 goat anti-rabbit and IRDye 
600 goat anti-mouse (1:15,000, LI-COR Biosciences) secondary anti-
bodies, membranes were imaged with the Odyssey Infrared Imaging 
System (LI-COR Biosciences). Band densitometry was performed 
using ImageJ 1.48 software (NIH), and relative protein expression was 
determined by normalizing to GAPDH. Fold changes were normalized 
to values of the control condition.
RNA extraction. Total RNA was extracted from HKC-8 or mouse kid-
neys using the miRNeasy Mini Kit (Qiagen) according to the manufac-
turer’s instructions. RNA quantity and quality were determined at 260 
nm by a Nanodrop-1000 spectrophotometer (Thermo Fisher Scientific).
Analysis of mRNA expression. Reverse transcription (RT) was car-
ried out with 500 ng of total RNA using the iScript cDNA Synthesis kit 
(Bio-Rad). qRT–PCR was carried out with the iQ SYBR Green Super-
mix (Bio-Rad), using a 96-well Bio-Rad CFX96 RT-PCR System with a 
C1000 Thermal Cycler according to the manufacturer’s instructions. 
A Ct value was obtained from each amplification curve using CFX96 
analysis software provided by the manufacturer. Relative mRNA 
expression was determined using the 2−ΔΔCt method (32). The 18S gene 
was used for normalization purposes. The primer sequences used for 
mRNA quantification are listed in Supplemental Table 3. Fold changes 
were normalized to values of the control condition.
Mouse models of kidney fibrosis. Mice were housed in the specific 
pathogen–free animal facility at the CBMSO in accordance with EU 
regulations for all the procedures. UUO, FAN, and ADN models are 
described in Supplemental Methods.
[1-14C]-palmitate oxidation. Measurement of FAO rates was per-
formed in mouse kidney tissue and cells as previously described (33). 
Kidneys from renal fibrosis mouse models were homogenized in 5 
volumes of chilled sodium chloride–Tris–EDTA buffer by a Dounce 
homogenizer. Next, 30 μL of tissue homogenate supernatant was 
mixed with 370 μL of the oxidation reaction mixture containing 7% 
BSA/5 mM palmitate/0.01 μCi/μL 14C-palmitate (PerkinElmer) and 
incubated at 37°C for 30 minutes. Cells were seeded in 12-well dishes 
to reach a confluence of 70% and were infected with CPT1A adenovi-
ruses as described in the adenovirus-mediated CPT1A overexpression 
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hours, embedded in paraffin, cut in serial sections (5 μm thickness), 
and stained with H&E, Sirius red, and periodic acid–Schiff (PAS) as 
described previously (41) Tissue sections for immunostaining were 
deparaffinized through xylene and hydrated through graded ethanol 
(100%, 96%, 90%, and 70%) and distilled water. Endogenous per-
oxidase was blocked. We incubated the tissue sections with 4% BSA 
for 1 hour at RT. Primary antibodies to detect CD3 (M7254, 1:100, 
Dako) were incubated for 30 minutes at RT. After washing, slides were 
incubated with goat anti-mouse HRP secondary antibody (“Visual-
ization Reagent HRP” from SK006, Dako) for 30 minutes and visu-
alized using the PD-L1 IHC 22C3 pharmDx (SK006, Dako). To detect 
Kim-1, primary antibody (AF1817, 1:500, R&D Systems) was incubated 
for 30 minutes at RT. To detect F4/80, primary antibody (MCA4976, 
1:50, BioRad) was incubated at 4°C overnight. After washing, slides 
were incubated with goat anti-rabbit IgG biotin-SP conjugate sec-
ondary antibody (31752, 1:200, Invitrogen) and rabbit anti-rat IgG 
biotin-SP (31834, 1:200, Thermo Fisher Scientific), respectively, and 
visualized using DAB Substrate Kit (ab64238, Abcam). Tissue sections 
were revealed using DAB (20 μL/mL, Dako) and counterstained with 
Carazzi’s hematoxylin. Slides were mounted with MOWIOL (Calbio-
chem). See Supplemental Methods for histological and immunohisto-
chemical analysis.
Electron microscopy examination. The number of mitochondria 
and their structure was analyzed by standard transmission electron 
microscopy. Renal cortex pieces were cut into small blocks (1 mm3) 
and fixed by immersion in fixative (4% paraformaldehyde/2% glutar-
aldehyde in 0.1 M phosphate buffer) overnight at 4°C. After washing 
with cold PBS, they were incubated in 1% osmium tetroxide and 1% 
potassium ferricyanide in water for 1 hour at 4°C. The pieces were 
sequentially stained with 0.15% tannic acid (in 0.1 M phosphate buf-
fer) for 1 minute at RT and 2% uranyl acetate in water for 1 hour at 
RT. Next, they were dehydrated in graded ethanol and embedded in 
EmBed812 resin (Electron Microscopy Sciences). Serial ultrathin sec-
tions (70 nm) of the tissue were collected on copper mesh grids. Three 
grids from each sample were examined using a JEOL 1230 transmis-
sion electron microscope, and digital photographs were captured by 
real-time digital imaging.
Adenovirus-mediated CPT1A overexpression. CPT1A overex-
pression in cells was driven and transduced by adenoviral particles. 
Adenoviruses carrying CPT1A (AdCPT1A) or adenovirus control 
(AdControl) were amplified, purified, and titrated according to Cal-
deron-Dominguez et al. (ref. 42, see Supplemental Methods for 
details). HCK8 cells were seeded into 60 mm culture dishes to reach 
a confluence of 70%. They were infected with adenoviruses AdCon-
trol and AdCPT1A (100 MOI) for 24 hours in serum-free DMEM/
F12 (supplemented with 15 mM HEPES, 5% FBS, 1× ITS, 0.5 μg/mL 
hydrocortisone, 50 units/mL penicillin, and 50 μg/mL streptomy-
cin), and then the medium was replaced with complete medium for 
an additional 24 hours. Adenovirus infection efficiency was assessed 
in AdControl-infected cells by immunofluorescence.
Clinical data. Acylcarnitines were evaluated based on the PRED-
IMED trial. The PREDIMED is a primary prevention, multicenter trial 
conducted in Spain. A detailed description of this trial is provided else-
where (13). Liquid chromatography–tandem mass spectrometry was 
used to semiquantitatively profile acylcarnitines in plasma samples. Our 
analysis is based on a subsample of 686 participants with metabolomics 
data and measures of kidney function, including GFR and urinary albu-
signal was analyzed by flow cytometry. Cells were gated by forward 
(FSC-A) and side scatter (SSC-A) and for single cells using FSC-A/
FSC-H. Next, dead cells were excluded. Fluorescence intensity was 
measured by flow cytometry using wavelengths (ex/em) 550/610 
(acceptor), 490/550 (donor), and 490/600 (FRET) in a FACSCanto II 
system (BD Biosciences) and analyzed with FlowJo 10.2 software. The 
ratio of FRET/donor was displayed as a histogram and its median of 
fluorescence intensity was obtained. For each experimental condition, 
at least 20,000 singlets were analyzed in triplicates.
Quantification of kidney cell populations by flow cytometry. Mul-
tiparametric flow cytometry was used for the identification of the 
macrophage and epithelial cell population. Kidneys were diced, incu-
bated at 37°C for 30 minutes with 0.5 mg/mL Liberase DL (Roche 
Basel) and 100 U/mL DNase (Roche Basel) in serum-free DMEM, 
and filtered (40 μm). For staining, 106 cells were dissolved in 50 μL 
of buffer and preincubated with 0.25 μL CD16/CD32 (BioLegend). 
Next, 3 μL of DAPI (1:15000) (Sigma-Aldrich) was added to stain dead 
cells. Cell suspensions were incubated with specific fluorochrome- 
conjugated antibodies (BioLegend) listed in Supplemental Table 5. For 
each experiment, flow minus one (FMO) controls were performed for 
each fluorophore to establish gates by using corresponding antibodies 
listed in Supplemental Table 5. Fluorescence intensity was measured in 
a FACSCanto II cytometer (BD Biosciences) and analyzed with FlowJo 
10.2 software. For each kidney sample, at least 20,000 singlets were ana-
lyzed in triplicates. Cell gating was initially based in the forward versus 
side scatter (FSC vs. SSC) plot. Next, dead cells were excluded. Identifi-
cation of the macrophage cell population was based on the presence of 
CD45, expressed in inflammatory and hematopoietic cells and F4/80, 
a specific macrophage surface marker. CD86 and CD206 were used to 
determine M1 and M2 macrophage subpopulations, respectively (38). 
Identification of the epithelial cell population was based on the pres-
ence of the epithelial cell adhesion molecule (EpCAM) and the absence 
of CD45. The subsequent display of positive CD24 determined injured 
proximal tubule epithelia (39). Numbers in quadrants indicate cell pro-
portions in the percentage of cells that coexpress both markers.
Measurements of OCR. FAO-associated OCR (ligated to oxidative 
phosphorylation) and ECAR (associated with lactate production and 
glycolysis) were studied using the Seahorse Bioscience metabolic ana-
lyzer for the XF Cell Mito Stress Test and Agilent Seahorse XF Real-
Time ATP Rate Assay according to the manufacturer’s instructions 
(40). See Supplemental Methods for details.
Immunofluorescence. A quarter piece of each kidney sample was 
immersed sequentially in 4% neutral buffered formalin for 24 hours, 
in 30% sucrose in PBS until tissue sank (6–12 hours), and embedded in 
Tissue-Tek OCT for cryoprotection at –80°C. OCT blocks were cut in 
serial frozen sections (10 μm thickness). These sections were fixed with 
4% PFA for 10 minutes and permeabilized with 0.25% Triton X-100 in 
PBS for 5 minutes at room temperature (RT). Next, they were blocked 
with 1% BSA in PBS for 30 minutes at RT and incubated for 1 hour for 
staining with specific primary antibodies and fluorochrome-conju-
gated secondary antibodies for 1 hour at RT (Supplemental Table 6). 
Nuclei were stained with DAPI (Sigma) for 5 minutes at RT. The cov-
erslips were mounted on slides using MOWIOL (Calbiochem). Tissue 
fluorescence was visualized by an LSM 510 Meta Confocal microscope 
with a 40×/1.3 oil Plan-Neofluar M27 objective (Zeiss).
Histology and immunohistochemistry. A quarter piece of each kid-
ney sample was immersed in 4% neutral buffered formalin for 24 
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tro de Investigación Biomédica en Red de Fisiopatología de la 
Obesidad y la Nutrición (CIBEROBN) CB06/03/0001 (DS), the 
Government of Catalonia 2017SGR278 (DS), and the Fundació 
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vación AGL-2009–13906-C02 and AGL2010–22319-C03; the 
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surements in PREDIMED were funded by NIH R01DK102896, 
F31DK114938, NIH/NHLBI 1R01HL118264, and NIH/NHLBI 
2R01HL118264. PREDIMED funding is related to MRC, MA-MG, 
and JS. VM was supported by predoctoral fellowships of the 
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065986) from MINECO. We acknowledge the J. David Gladstone 
Institutes and Ken Nakamura (University of California) for pro-
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min-creatinine ratio (43, 44). Studies of CPT1A expression in kidney 
tubules were performed in a cohort of 433 patients described in Becker-
man et al. (45) and herein named the CKD cohort, whose demographic 
and clinical features are summarized in Supplemental Table 9.
See complete unedited blots in the supplemental material.
Statistics. Data in experimental models were analyzed using non-
parametric tests except where indicated. The difference between 2 
independent groups was examined with the Mann-Whitney U test; 
more than 2 groups were compared with the Kruskal-Wallis test. A P 
value of 0.05 or less was considered statistically significant. Data were 
analyzed using GraphPad Prism 6.0. Data are reported as mean ± 
SEM. See Supplemental Materials for statistics of data in clinical stud-
ies for acylcarnitines and CPT1A expression.
Study approval. Animals were handled in agreement with the 
Guide for the Care and Use of Laboratory Animals contained in Direc-
tive 2010/63/EU of the European Parliament. Approval was granted 
by the CBMSO Ethics Committee for Animal Experimentation of the 
CBMSO in Madrid, the ethics committee from Consejo Superior de 
Investigaciones Científicas (CSIC), and the Regulatory Unit for Ani-
mal Experimental Procedures from the Comunidad de Madrid. For 
human studies, written informed consent of participants is specified 
in the references (44, 45).
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